Analyst Reco. BELLUS Health

Equities

BLU

CA07987C2040

Delayed Toronto S.E. Other stock markets 21:00:00 29/06/2023 BST			5-day change	1st Jan Change
19.48 ^CAD	-0.10%		-.--%	-.--%

2023	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Capped Composite Index	CI
2023	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Completion Index	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Downgrades BELLUS Health to Sector Perform From Outperform, Cuts Price Target to $14.75 From $21 Amid GSK Deal; Speculative Risk Kept	19/04/23	MT
Slide in commodity prices pushes TSX futures lower	19/04/23	RE
Jefferies Downgrades BELLUS Health to Hold From Buy, Cuts Price Target to $14.75 From $21	18/04/23	MT
BTIG Downgrades BELLUS Health to Neutral From Buy	18/04/23	MT
TD Cowen Downgrades BELLUS Health to Market Perform From Outperform, Adjusts Price Target to $14.75 From $15	18/04/23	MT
LifeSci Capital Downgrades BELLUS Health to Market Perform From Outperform, Adjusts Price Target to $14.75 From $24	18/04/23	MT
Evercore ISI Group Downgrades BELLUS Health to In Line From Outperform, Adjusts Price Target to $14.75 From $24	18/04/23	MT
RBC Capital on Bellus Health -- Maintains US$21 PT, Outperform/Speculative Risk Rating	15/11/22	MT
RBC Capital Raises Bellus Health Target to US$21, Maintains Outperform/Speculative Rating	30/09/22	MT
RBC Raises Price Target on BELLUS Health to $21 From $19, Maintains Outperform, Speculative Risk	30/09/22	MT
Jefferies Adjusts BELLUS Health's Price Target to $21 From $14, Reiterates Buy Rating	23/09/22	MT
HC Wainwright Increases BELLUS Health's Price Target to $20 From $16, Keeps Buy Rating	11/08/22	MT
RBC Boosts Price Target on BELLUS Health to $19 From $14, Maintains Outperform-Speculative Risk Rating	13/07/22	MT
RBC Capital Raises Price Target for BELLUS Health to $19 From $14, Maintains Outperform Rating	12/07/22	MT
RBC Capital on Bellus Health's BLU-5937'S Path Forward	01/04/22	MT
RBC Capital Keeps Outperform/Speculative, US$14 TP on Bellus, Says Physician Surveys Suggest Enthusiasm For PX23 Class	18/03/22	MT
RBC Capital Markets Maintains BELLUS Health's Rating, Price Target	01/03/22	MT
RBC Capital Reiterates Outperform/Speculative Risk, US$14 TP on Bellus Health	24/02/22	MT
HC Wainwright Adjusts BELLUS Health's Price Target to $16 From $14, Reiterates Buy Rating	24/02/22	MT
RBC Capital Keeps Outperform/Speculative Risk, US$14 TP on Bellus Health	04/02/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BELLUS Health

Equities

BLU

CA07987C2040

Analyst Reco.

Filters